Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T13:45:32.871Z.
Calculation as of: 2026-10-06T13:45:32.871Z.
Quote observation: 2026-10-06T13:45:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
EARNINGS YIELD
N/A
Market Cap
$848.19M
Earnings Yield
N/A
TTM Avg
2.16%
3Y Avg
2.16%
5Y Avg
2.16%
Market Cap
$884.63M
Earnings Yield
N/A
TTM Avg
2.57%
3Y Avg
2.57%
5Y Avg
2.57%
Market Cap
$804.39M
Earnings Yield
N/A
TTM Avg
0.49%
3Y Avg
4.33%
5Y Avg
4.33%
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Apnimed, Inc. (APMD) | $847.84M | N/A | N/A | N/A | N/A |
| Jade Biosciences, Inc. (JBIO)vs › | $852.65M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $848.19M | N/A | 2.16% | 2.16% | 2.16% |
| Beta Bionics, Inc. (BBNX)vs › | $857.50M | N/A | N/A | N/A | N/A |
| Alumis Inc. (ALMS)vs › | $837.98M | N/A | N/A | N/A | N/A |
| Ardelyx, Inc. (ARDX)vs › | $823.84M | N/A | 0.51% | 0.51% | 0.51% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $884.63M | N/A | 2.57% | 2.57% | 2.57% |
| InMode Ltd. (INMD)vs › | $813.07M | 8.70% | 11.03% | 10.77% | 8.20% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $804.39M | N/A | 0.49% | 4.33% | 4.33% |
| Arbutus Biopharma Corp (ABUS)vs › | $905.71M | 17.02% | 17.36% | 17.36% | 17.36% |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
